<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550314</url>
  </required_header>
  <id_info>
    <org_study_id>TRIENT1328</org_study_id>
    <nct_id>NCT02550314</nct_id>
  </id_info>
  <brief_title>A Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18</brief_title>
  <official_title>A Phase III Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18-multicenter,Investigator Initiated Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of the regeneration treatment of tympanic membrane with
      NPC-18 and FBG-18.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Closure of tympanic membrane perforation in the observation period at16 wks</measure>
    <time_frame>Closure of tympanic membrane perforation in the observation period at16 wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Closure of tympanic membrane perforation in the observation period at 4 wks</measure>
    <time_frame>Closure of tympanic membrane perforation in the observation period at 4 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of hearing level in the observation period at 4 wks and 16 wks</measure>
    <time_frame>Improvement of hearing level in the observation period at 4 wks and 16 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Air-bone gap in the observation period at 4 wks and 16 wks</measure>
    <time_frame>Air-bone gap in the observation period at 4 wks and 16 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference of the average hearing level of air conduction threshold from the treatment at 0 wk and observation period at 4wks and 6 wks</measure>
    <time_frame>The difference of the average hearing level of air conduction threshold from the treatment at 0 wk and observation period at 4wks and 6 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average hearing level of air conduction threshold in the observation period at 4 wks and 16 wks</measure>
    <time_frame>Average hearing level of air conduction threshold in the observation period at 4 wks and 16 wks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Tympanic Membrane Perforation</condition>
  <arm_group>
    <arm_group_label>NPC-18,FBG-18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention drug:
NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue
Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fiblast,gelatin sponge,fibrin glue</intervention_name>
    <arm_group_label>NPC-18,FBG-18</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed concent obtained

          2. At the time of obtaining informed consent, Ages ranged from over 20 to 80

          3. At the time of obtaining informed consent, only those with tympanic membrane
             perforation in 1 ear (not both) for over 6 months (perforation in both ears is
             excluded)

        Exclusion Criteria:

          1. TMP caused by burn or radiation therapy

          2. In patients with chronic otitis media with ear drum perforation, tympanic cavity are
             not dry

          3. Inflammatory,infection or otorrhea in patient's eardrum,earcanal,middle ear and
             tympanic cavity

          4. No invasion of epithelial and no cholesteatoma in tympanic cavity or around perforated
             edge

          5. History of tympanoplasty

          6. A Part of the eardrum adhered to tympanic cavity

          7. By temporal bone CT, soft tissue shadow in mastoid antrum or tympanic (using a CT
             image of less than 12 wks before patients registration)

          8. Abnormality in the chain and ear ossicles

          9. Air-bone gap difference more than 25dB by patch hearing test

         10. Unable to see whole edge of TMP due to narrow external auditory canal

         11. Unable to wash out Ear drops during the treatment period

         12. Presenting with uncontrolled diabetes (NGSP HbA1c 6.9% and more)

         13. Presenting with autoimmune disease

         14. History of malignancy within 3 years prior to obtained informed concent

         15. Administration of immunosuppressive agent or anti-cancer-agent

         16. History of Allergic reaction to local anesthetic(Xylocaine), bFGF(Fiblast spray),
             fibrin glue(Beriplast P Combi set, etc.), gelatin sponge formulation(spongel) and
             others

         17. Though out the period from screening to treatment, patient who is unable to wash out
             &quot;Thrombolytic agent&quot;, &quot;Anticoagulant&quot;, &quot;Anti-platelet agent&quot;, &quot;Procoagulant agent&quot;,
             &quot;anti-line solvent&quot;and&quot;aprotinin formulation&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</investigator_affiliation>
    <investigator_full_name>Shin-ichi Kanemaru</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tympanic Membrane Perforation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

